Re-analysis of cancer vaccine patients with immune-related clinical response criteria (iRRC)

Kentaro Nishida, Takuro Saito, Shinya Urakawa, Masaki Mori, Kazuhiro Kakimi, Yuichiro Doki, Hisashi Wada

Research output: Contribution to journalArticlepeer-review


Anti-tumor responses induced by immunotherapy such as cancer vaccine are presumed to be mediated by induction of cancer-specific immune responses. Therefore, the immune-related response criteria (irRC) have been applied for cancer immunotherapies instead of the Response Evaluation Criteria in Solid Tumors (RECIST). Clinical responses of 91 patients enrolled in our cancer vaccine clinical studies were evaluated using RECIST. In this study, we re-analyzed their clinical responses using irRC. We identified 2 patients whose responses were evaluated as PD by RECIST, but as PR and SD by irRC, respectively. As these 2 patients showed relatively long survival rate, we concluded that irRC was suitable for the assessment of clinical outcomes in cancer immunotherapy.

Original languageEnglish
Pages (from-to)1466-1468
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Issue number10
Publication statusPublished - Oct 2018

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Re-analysis of cancer vaccine patients with immune-related clinical response criteria (iRRC)'. Together they form a unique fingerprint.

Cite this